Nestle pays $2 billion to secure Aimmune's allergy treatment

ZURICH - Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics , as the Swiss company expands its fast-growing health science business.

Nestle said in a statement that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it already has a stake of around 25.6%, at $2.6 billion. Nestle estimates that up to 240 million people worldwide suffer from food allergies, with peanut allergy being the most common, and with Aimmune, NHS will have prevention, diagnostic and medical treatment options available, Behar said.

The NHS business was on track to more than double sales by 2022, from 2 billion Swiss francs in 2014, and was expected to close 2020 at 3.3 billion francs, he added.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Surf Air secures US$200m funding commitment on upcoming IPOSurf Air Mobility, a membership-based private plane operator, has secured a US$200 million funding commitment from Global Emerging Markets Group (GEM) for when it goes public. Read more at The Business Times.
Source: BusinessTimes - 🏆 15. / 51 Read more »

Reliance to buy Future Group's retail arm for US$3.38 billionMukesh Ambani-led Reliance Industries said on Saturday it has agreed to acquire the retail and wholesale business and the logistics and ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

How the UK restarted its restaurant industry: Paying half the bill
Source: TODAYonline - 🏆 1. / 99 Read more »